Mirati Therapeutics Inc.
(NASDAQ : MRTX)

( )
MRTX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.03%183.551.1%$846.87m
GILDGilead Sciences, Inc.
-1.04%80.700.9%$816.69m
CELGCelgene Corporation
-0.92%95.261.2%$791.42m
JUNOJuno Therapeutics, Inc.
-0.41%85.1013.5%$584.15m
BIIBBiogen Inc.
-2.51%291.871.2%$500.99m
REGNRegeneron Pharmaceuticals, Inc.
-0.31%332.152.7%$399.78m
VRTXVertex Pharmaceuticals Incorporated
-0.14%160.721.9%$358.41m
ALXNAlexion Pharmaceuticals, Inc.
-1.83%120.472.0%$256.63m
NKTRNektar Therapeutics
1.57%83.436.0%$246.17m
ILMNIllumina, Inc.
0.03%229.203.5%$234.08m
BLUEBluebird Bio, Inc.
2.25%213.3516.1%$201.76m
AAgilent Technologies, Inc.
-0.11%71.941.5%$173.78m
INCYIncyte Corporation
0.51%86.032.5%$158.32m
EXASExact Sciences Corporation
-0.57%48.8626.0%$132.16m
BMRNBioMarin Pharmaceutical Inc.
-0.16%84.984.4%$122.34m

Company Profile

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of oncology products to treat genetic and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.